Journal of Genetic Syndromes & Gene Therapy
Open Access

Advances in Precision Medicine through Genetics and Inherited Retinal Diseases

Laurra Bruneell^{* *}Correspondence: Laurra Bruneell, Department of Speech, Language and Hearing Sciences, Ghent University, Gent, Belgium, Email:

Author info »

Description

The Inherited Retinal Diseases (IRDs) have advanced significantly from the last decade as a result of major advances in molecular biology and genetic technologies. The IRD molecular genetics not only provides a better understanding of the underlying pathogenesis but also allows for the development of new therapeutic options which examines the molecular genetic characteristics and genetic analysis techniques associated with IRDs. We also go over the molecular biology of the most common mutations that cause Infant Respiratory Distress Syndrome (IRDS). IRDS are a clinically and genetically diverse group of inherited eye disorders characterized by rod and cone photoreceptor degeneration, such as Retinitis Pigmentosa (RP), Leber Congenital Amaurosis (LCA), Stargardt Disease (STGD), Best Vitelliform Macular Dystrophy (BVMD), and Usher Syndrome (USH).

The estimated prevalence varies by 1RD subtype: 1/3000-1/50,000 for RP, 1/50,000-1/33,000 for LCA, 1/8000-1/10,000 for STGD, 1/5000-1/67,000 for BVMD, and 1/30,000 for USH. Clinically they can be classified using the criteria of cell type or anatomical location is primarily affected among rod photoreceptors RP, rod-cone dystrophy, cone photoreceptors, macular dystrophy and choroidal dystrophy choroideremia, central molar Presently, The majority of IRDs are diagnosed based on clinical findings.

Techniques of genetic analysis

However, the variable of onset, genotypic heterogeneity one phenotype caused by multiple genes, phenotypic heterogeneity various mutations in a single gene resulting in different phenotypes incomplete penetrance, unclear inheritance, and progressive nature of IRDs makes definitive diagnosis difficult. As a result, molecular genetic testing is required for the definitive diagnosis of IRDs after the OAT gene was to cause gyrate atrophy the methods and tools for molecular genetic diagnosis of IRDs evolved continuously. Currently, over 270 genes have been identified as being linked to IRDs. In general, the goal of genetic analyses is to identify and correlate genomic variations such as Single Nucleotide Variants (SNVs), small DNA insertions or deletions (indels), Copy Number Variations (CNVs), or other Structural Variants (SVs) with human phenotypes. Direct analysis of the targeted gene mutation, direct sequence analysis, or linkage study can be used to make a molecular genetic diagnosis. When the related gene has been identified, direct mutation analysis is possible. This approach, however, is less useful for IRDs because of more than 270 disease-related genes because of genotype and phenotypic heterogeneity, as well as unclear inheritance patterns, it is difficult to select genes for direct mutation analysis. Given the extreme heterogeneity of IRDs, Next-Generation Sequencing (NGS), also known as massively parallel sequencing, has been proposed as a low-cost method for identifying mutations with the introduction of NGS, it is now possible to analyze all genes within a specific linkage interval of targeted NGS, all exons in the genome Whole Exome Sequencing (WES), and even the entire genomic sequence Whole Genome Sequencing (WGS) the characteristics of common NGS methods.

NGS has improved in accuracy and throughput over the last decade. Because of their wide genetic and phenotypic heterogeneity, IRDs are excellent candidates for NGS screening. The most significant barrier to clinical NGS application is the massive amount of data to analyze. For each exome 1171, for example, the number of variants detected ranges between 20,000 and 50,000. After the application of various bioinformatics filters, at least 150-500 variants remain as "probable pathogenic." In the clinical setting, interpreting these variants is a difficult task 1181. Another barrier in NOS is the higher error rate compared to Sanger sequencing. The false-positive rate of NGS is between 14 and 27%. Artificial mutations generated during template amplification or sequencing can produce false-positive results. As a result, each type of variant discovered through NGS must be validated through Sanger sequencing, which increases the cost and turnaround time.

Next-generation sequencing

Sequencing of the Entire Genome WGS sequences the entire genome, including both coding (exons) and non-coding regions (introns, regulatory, and intergenic sequences). This enables the detection of CNVs, intergenic variations, and other structural rearrangements, as well as exonic sequences, which can cover more than 95% of the human genome. WGS has exceptional power, especially for detecting three types of pathogenic variants SVs, variants in GC-rich regions, and variants in non-coding regulatory regions, where coverage is significantly improved over WES 1421. Furthermore, recent research suggests that IRDs 143 and 44J may be caused by variants in microRNA regions and deep intronic regions. As the cost of WGS continues to fall, more laboratories have access to the technology. However, analyzing massive amounts of genomic variant data remains a challenge.